Acumen Pharmaceuticals, Inc. Common Stock (ABOS)

Publicly reported company facts and saved market data for Acumen Pharmaceuticals, Inc. Common Stock (ABOS), with sources and as-of times. Saved data is not a live quote.

Company profile

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AOs) for the treatment of Alzheimer's disease (AD). Acumen's scientific founders pioneered research on AOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer's disease pathology. Acumen is currently focused on advancing its lead investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer's disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme's proprietary ENHANZE drug delivery technology.

Company facts

Sector: Health Care
Industry: Biological Products, (No Diagnostic Substances)
Market cap: $15.2M · as of 2026-10-30
Incorporated in: United States
Company website: www.acumenpharm.com
Exchange: NASDAQ

Saved quote

Saved snapshot, not a real-time quote. Check the market time before relying on it.

Last reported price: $0.2226
Reported change: -90.28%
Reported volume: 68,104,973
Latest market time: 2026-10-30 19:59 ET

Float and shares outstanding

ABOS float references and SEC-reported shares outstanding
Measure	Shares	As of	Source and basis
Float	40,613,569	2026-08-13	Reported by a single source; not cross-checked.
Shares outstanding (O/S)	72,327,320	2026-10-21	SEC 10-Q filing · filed 2026-10-26

Dates are measurement dates, not the time FennEdge retrieved the data. Float references are listed separately; they are not averaged or adjusted for later splits or share issuances.

Short interest

Reported short interest: 3,090,758 shares
Settlement date: 2026-10-15
Source: Market and company data

Exchange-published short interest for the stated settlement date, not a live short position.

Recent daily sessions

The 10 most recent saved daily sessions, through 2026-10-29. Daily OHLC and volume; not real-time.

ABOS daily open, high, low, close and volume
Date	Open	High	Low	Close	Volume
2026-10-29	2.40	2.52	2.29	2.29	808,044
2026-10-28	2.28	2.50	2.26	2.38	1,407,894
2026-10-27	2.25	2.37	2.10	2.26	1,797,777
2026-10-26	2.13	2.42	1.97	2.27	1,649,956
2026-10-23	2.05	2.05	1.90	1.98	541,794
2026-10-22	2.03	2.14	2.01	2.06	569,491
2026-10-21	2.00	2.08	1.99	2.03	397,705
2026-10-20	1.78	2.07	1.76	2.02	784,618
2026-10-19	1.70	1.78	1.67	1.77	274,683
2026-10-16	1.67	1.72	1.62	1.69	449,342

Dilution timeline

As of 2026-10-30T23:50:12.466221+00:00

2026-10-28 · EFFECT · Effectiveness notice filed
2026-10-26 · S-3 · Shelf registration filed
2026-04-01 · 424B3 · Prospectus filed
2026-04-01 · EFFECT · Effectiveness notice filed
2026-03-26 · S-3 · Shelf registration filed
2026-03-16 · 8-K · Current report filed
2025-11-13 · 424B5 · Prospectus filed
2024-03-27 · S-3 · Shelf registration filed

Parsed share counts, prices and warrant terms require Plus or above. Explore plans

Research this company

FennEdge organizes SEC filings and reported market data. Sign in for additional research and your private trading context.